A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521407-52-00

Acronym

89862175LUC1001

Enrollment

120

Registered

2025-11-21

Start date

2025-12-16

Completion date

Unknown

Last updated

2025-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026